CSIMarket
 


Painreform Ltd  (PRFX)
Other Ticker:  
 

Painreform Ltd's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Painreform Ltd in the forth quarter 2022?
Painreform Ltd recorded a cumulative net loss of $-9 million during 12 months ending in the forth quarter 2022, resulting in a negative return on equity (ROE) of -79.77%.

Within the Major Pharmaceutical Preparations industry 322 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2022 from 0 to 4145.

What is ROE?



Return On Equity (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Equity Change -39.05 % -39.05 % -39.05 % -39.05 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -9 -7 -7 -7 -7
Return On Equity (TTM) -79.77 % -56.67 % -49.8 % -44.41 % -40.07 %
PRFX's Total Ranking # 4145 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 11 11 11 11 18
Seq. Equity Change 0 % 0 % 0 % -39.05 % 0 %
Seq. Net Income Change - - - - -

Return On Equity Company Ranking
Within: No.
Industry # 323
Sector # 704
Overall # 4145

Return On Equity Statistics
High Average Low
-40.07 %
-59.92 %
-79.77 %
(Dec 31 2021)   (Dec 31 2022)



  News about Painreform Ltd

PainReform CEO Ilan Hadar Discusses PRF-110's Potential in Combating the Opioid Epidemic


Introduction
In a recent interview with Proactiveinvestors.com, PainReform Ltd.'s CEO, Ilan Hadar, shed light on the latest developments surrounding PRF-110 and its potential to address the concerning opioid epidemic. As a clinical-stage specialty pharmaceutical company, PainReform focuses on reformulating established therapeutics to provide safer and more effective solutions for pain management. This article explores the key insights shared by Hadar and highlights the significance of PRF-110 in tackling the current opioid crisis.
PainReform's Remarkable Progress
PainReform Ltd. has made significant strides in its mission to combat the opioid epidemic through the development of PRF-110. This novel drug is a long-lasting formulation of the commonly used anesthetic ropivacaine and holds great promise in offering prolonged pain relief without the risk of addiction associated with opioids.




PRFX Annual Return On Equity (Dec 31 2022)
2022
(Dec 31 2021)
2021



Total Equity in Millions 11 18 0 0 0
Y / Y Equity Change -39.05 % - - - -
Net Income in Millions -9 -7 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity -79.77 % -40.07 % - - -





More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PRFX's' Return on Equity at Yahoo Finance
PRFX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Roe for PRFX's Competitors
Return On Equity for Painreform Ltd's Suppliers
Roe for PRFX's Customers




Companies with similar Return On Equity at Dec 31 2022, within Healthcare Sector ROE


Date modified: 2023-03-24T11:38:10+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com